General Information |
| Summary |
This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage. |
| Clinical trials phase |
Phase 1 |
| Start date (estimated) |
2021-11-24 |
| End date (estimated) |
2040-02-29 |
| Clinical feature |
| Label |
multiple myeloma |
| Link |
http://purl.obolibrary.org/obo/DOID_9538 |
| Description |
A myeloid neoplasm that is located_in the plasma cells in bone marrow.; OMIM mapping confirmed by DO. [SN]. |
|
Administrative Information |
| NCT number |
NCT05182073 |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=NCT05182073 |
| Other study identifiers |
|
| Source weblink |
https://clinicaltrials.gov/ct2/show/NCT05182073 |
| Regulatory body approval |
| Name |
Food and Drug Administration (FDA) |
| Country |
|
|
| Public contact |
| Email |
FateTrialDisclosure@fatetherapeutics.com |
| Public email |
FateTrialDisclosure@fatetherapeutics.comFateTrialDisclosure@fatetherapeutics.com |
| First name |
Fate Trial Disclosure |
| Last name |
Fate Trial Disclosure |
| Phone |
+1 866-875-1800 |
| Country |
|
|
| Sponsors |
Fate Therapeutics
|
Cells |
| Which differentiated cell type is used |
| Label |
natural killer cell |
| Link |
http://purl.obolibrary.org/obo/CL_0000623 |
| Description |
A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells. |
|
Recruitment |
| Recruitment Status |
Recruiting |
| Estimated number of participants |
168 |
